Navigation Links
ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11

Company CEO is featured speaker: "Case Study - Screening Ion Channels for

Safety and Efficacy" on Friday, September 26 at 11:30

CLEVELAND, Sept. 18 /PRNewswire/ -- ChanTest will feature its expanding line of ion channel services and cell lines for drug-discovery and development applications in booth 11 at the Assays and Cellular Targets conference in San Diego, September 24-26. ChanTest designed its ion channel cell lines and services to provide drug-discovery researchers the early information they need to identify the most promising target compounds and eliminate those that could ultimately cause harmful side effects. ChanTest is also working with pharmaceutical and biotech companies to help rescue shelved pharmaceutical compounds.

Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will present a case study to conference participants entitled, "Screening Ion Channels for Safety and Efficacy," on Friday, September 26 at 11:30, as part of the conference's Ion Channel Targets track. "We are developing a library of ion channel-expressing cell lines for screening with the full range of automated patch clamp instruments and FLIPR-Tetra(r)," said Dr. Brown. "At present, 86 'books' are available and 160 will be available by June 2009. We validate each cell line for cDNA sequence, Western blot, voltage range, gating, and pharmacology. We recognize that each research program has its own unique needs and priorities, so we've designed our services and cell lines to offer the most flexibility possible. Our validated ion channels can be mixed and matched into panels according to tissue, e.g., cardiac; therapeutic area, e.g., pain; and ion channel family, e.g., TRP channels. And we draw upon our years of ion channel experience to help customers design an appropriate testing program to meet their specific scientific and budgetary goals."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

The A/C/T Assays and Cellular Targets conference and exhibition takes place September 24-26, 2008 at the Marriott San Diego Hotel & Marina in California.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 18,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
2. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
4. ChanTest Launches Redesigned Web Site
5. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
9. Neuralstem Reports Second Quarter Financial Results and Highlights
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
Post Your Comments:
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "2016 ... Sales Forecasts, Innovative Technologies, Competitive Strategies, Opportunities ... report to their offering. --> ... the "2016 Europe Cell Surface Markers: ...
(Date:12/1/2015)... , Dec. 1, 2015  Symic, a clinical-stage ... the extracellular matrix (ECM), today announced that it has ... advance the company,s pipeline, including its lead candidates SB-030 ... and includes the participation by all existing major investors, ... brings the total capital raised by Symic to over ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... -- An interventional radiology technique shows promise for helping morbidly obese ... study being presented today at the annual meeting of the ... --> --> Gastric ... as a way to stop bleeding in emergency situations, but ... treating obesity is new. Mubin Syed , M.D., ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific ... children, doctors and other healthcare providers face challenges in ... families and patients. In addition, as more children continue ... a patient,s adulthood and old age. John ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
Breaking Biology News(10 mins):